Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in riā¦ read more
Healthcare
Drug ManufacturersāGeneral
53 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$56.39
Price-0.11%
-$0.06
1Y
Price
Market Cap
$115.152b
Large
Price/Earnings 3y Avg5y Avg
15.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+32.3%
EBITDA Margin+23.3%
Net Profit Margin+6.6%
Free Cash Flow Margin+32.3%
EBITDA Margin+23.3%
Net Profit Margin+6.6%
Free Cash Flow MarginRevenue
$48.482b
+0.6%
1y CAGR+2.6%
3y CAGR+1.3%
5y CAGREarnings
$7.275b
+3.2%
1y CAGR-9.8%
3y CAGR-0.7%
5y CAGREPS
$3.56
+3.2%
1y CAGR-10.9%
3y CAGR-0.5%
5y CAGRBook Value
$20.102b
$86.476b
Assets$66.374b
Liabilities$44.460b
DebtDebt to Assets
51.4%
3.2x
Debt to EBITDAFree Cash Flow
$11.908b
-7.3%
1y CAGR-1.6%
3y CAGR+0.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company